Skip to content

MaxCyte MXCT Additional Paid-In Capital

Additional Paid-In Capital at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$490.5M+3.1%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
$6.67B+1.5%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$198.9M+123%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
$556.61M+0.9%
Repligen logo
RepligenRGEN
$1.65B+2.2%
TEC
Bio-TechneTECH
$1.01B+11.4%

Other financials

Income statement

See full
Revenue$9.7M-7.1%
Gross profit$8.1M-9.1%
Operating income-$6.2M+49.7%
Net income-$4.8M+53.7%
EPS (diluted)-$0.04+60.0%

Balance sheet

See full
Cash & equivalents$14.6M-37.8%
Total debt$17.5M-7.1%
Total equity$167.9M-15.8%
Total assets$194.5M-15.4%

Cash flow

See full
Operating cash flow-$8.2M+43.3%
CapEx$72.0K-89.0%
Free cash flow-$8.2M+45.3%

Valuation

See full
Market cap$130.15M-46.8%
Enterprise value$133.08M-46.3%
P/S-2.8×

Profitability

See full
Gross margin80.5%-0.4pp
Operating margin-141.8%+6.4pp
Net margin-121.2%+12.3pp
FCF margin-90.9%+3.7pp

Returns & leverage

See full
Return on equity-21.3%+2.0pp
Debt / equity0.1×0.0×
Current ratio12×-0.2×

Where this comes from

Reported directly by MaxCyte in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MaxCyte's additional paid-in capital?
MaxCyte (MXCT) reported additional paid-in capital of $433.05M in Q1 2026.
How has MaxCyte's additional paid-in capital changed year-over-year?
MaxCyte's additional paid-in capital increased by 1.8% year-over-year, from $425.46M to $433.05M.
What is the long-term trend for MaxCyte's additional paid-in capital?
Over 5 years (2020 to 2025), MaxCyte's additional paid-in capital has grown at a 27.6% compound annual growth rate (CAGR), from $127.67M to $431.91M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.